2022 Annual Meeting | C63 - Cutting-edge Concepts and Applications in Technology, Cellular Therapy, Imaging, and Interventions and Rehabilitation of Stroke

Date Monday 04/04/22

Time 07:00 AM - 09:00 AM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Pierre Fayad, MD, FAHA, FAAN

Topic(s) Cerebrovascular Disease and Interventional Neurology

Learning Objectives By the end of the course the participants will become familiar with the state-of-the art approach to the prevention, acute management and functional restoration of patients with stroke with a perspective on what is coming through the pipeline. Building on a brief summary update, participants will gain an overview of ongoing trials, remaining knowledge gaps and promising imaging, technological, and scientific advances that could potentially provide solutions to our knowledge gaps.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Systems-based Practice

Program Level Advanced

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Didactic

Program Materials Program Evaluations

Event Timeline
07:00 AM - 07:05 AM PDT	Introduction	Overview of Session and Introduction of Speakers Pierre Fayad, MD, FAHA, FAAN
07:00 AM - 07:00 AM PDT	Speaker	walk in slides Pierre Fayad, MD, FAHA, FAAN
07:05 AM - 07:35 AM PDT	Speaker	Promising Advances in the Acute and Interventional Management of Stroke Raul G. Nogueira, MD
07:35 AM - 08:05 AM PDT	Speaker	State-of-the-Art and Promising Advances in Stroke Recovery and Restoration Wayne W. Feng, MD, FAAN
08:05 AM - 08:35 AM PDT	Speaker	State-of-the-Art and Promising Advances in Stroke Prevention Pierre Fayad, MD, FAHA, FAAN
08:35 AM - 09:00 AM PDT	Q&A	Panel Discussion & Questions and Answers

Faculty Disclosures
Pierre Fayad, MD, FAHA, FAAN	Dr. Fayad has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. Dr. Fayad has received personal compensation in the range of $0-$499 for serving as a Member Data Safety & Monitoring Committee with NINDS.
Raul G. Nogueira, MD	Dr. Nogueira has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for for advisory roles with Anaconda, Biogen, Cerenovus, Genentech, Hybernia, Imperative Care, Medtronic, Phenox, Philips, Prolong Pharmaceuticals, Stryker Neurovascular, Shanghai Wallaby, and Synchron (consulting fees) as well as for advisory roles with Astrocyte, Brainomix, Cerebrotech, Ceretrieve, Corindus Vascular Robotics, Vesalio, Viz-AI, RapidPulse and Perfuze ( stock options). Dr. Nogueira has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Law Firms. Dr. Nogueira has received stock or an ownership interest from Viz-AI, Perfuze, Cerebrotech, Reist/Q'Apel Medical, Truvic, and Viseon. The institution of Dr. Nogueira has received research support from Cerenovus.
Wayne W. Feng, MD, FAAN	Dr. Feng has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Namsa. The institution of Dr. Feng has received research support from NIH. The institution of Dr. Feng has received research support from American heart association . The institution of Dr. Feng has received research support from Ipsen.

��ɫ��

��ɫ��